References
1. Petersen, J., et al., A model to predict the risk of
aspirin/non-steroidal anti-inflammatory drugs-related upper
gastrointestinal bleeding for the individual patient. Basic Clin
Pharmacol Toxicol, 2020. 126(5): p. 437-443.
2. Lee, M.W. and P.O. Katz, Nonsteroidal Antiinflammatory Drugs,
Anticoagulation, and Upper Gastrointestinal Bleeding. Clin Geriatr Med,
2021. 37(1): p. 31-42.
3. Lanas, A. and C.J. Gargallo, Management of low-dose aspirin and
clopidogrel in clinical practice: a gastrointestinal perspective. J
Gastroenterol, 2015. 50(6): p. 626-37.
4. Lenti, M.V., et al., Mortality rate and risk factors for
gastrointestinal bleeding in elderly patients. Eur J Intern Med, 2019.
61: p. 54-61.
5. Griffin, M.R., Epidemiology of nonsteroidal anti-inflammatory
drug-associated gastrointestinal injury. Am J Med, 1998. 104(3a): p.
23S-29S; discussion 41S-42S.
6. de Groot, N.L., et al., Primary non-variceal upper gastrointestinal
bleeding in NSAID and low-dose aspirin users: development and validation
of risk scores for either medication in two large Dutch cohorts. Journal
of Gastroenterology, 2014. 49(2): p. 245-253.
7. Solomon, D.H., et al., Derivation and Validation of a Major Toxicity
Risk Score Among Nonsteroidal Antiinflammatory Drug Users Based on Data
from a Randomized Controlled Trial. Arthritis Rheumatol, 2019. 71(8): p.
1225-1231.
8. Lee, S., et al., Impact of Preventive Strategies on Gastrointestinal
Complications in Elderly Patients on Concomitant Use of Oral
Anticoagulants and Nonsteroidal Anti-Inflammatory Drugs: A Nationwide
Cohort Study. Drug Saf, 2022. 45(3): p. 297-304.
9. Park, E.S., et al., Venous Thromboembolism in Children and Young
Adults in Korea: Analysis of the Korean Health Insurance Review and
Assessment Service Database. J Korean Med Sci, 2019. 34(49): p. e316.
10. ATC/DDD Index 2021. 2021.
11. Masclee, G.M., et al., Risk of upper gastrointestinal bleeding from
different drug combinations. Gastroenterology, 2014. 147(4): p.
784-792.e9; quiz e13-4.
12. Kim, T.J., et al., Effectiveness of acid suppressants and other
mucoprotective agents in reducing the risk of occult gastrointestinal
bleeding in nonsteroidal anti-inflammatory drug users. Sci Rep, 2019.
9(1): p. 11696.
13. Hong, W., et al., Development and validation of a risk prediction
score for severe acute pancreatitis. Journal of Translational Medicine,
2019. 17(1): p. 146.
14. Schöning, V., et al., Development and validation of a prognostic
COVID-19 severity assessment (COSA) score and machine learning models
for patient triage at a tertiary hospital. J Transl Med, 2021. 19(1): p.
56.
15. Ajnakina, O., et al., Development and validation of prediction model
to estimate 10-year risk of all-cause mortality using modern statistical
learning methods: a large population-based cohort study and external
validation. BMC Med Res Methodol, 2021. 21(1): p. 8.
16. Rücker, G. and M. Schumacher, Summary ROC curve based on a weighted
Youden index for selecting an optimal cutpoint in meta-analysis of
diagnostic accuracy. Stat Med, 2010. 29(30): p. 3069-78.
17. Krishnan, J.A., et al., Biomarkers to Predict Response to ICS and
LAMA in Adolescents and Adults with Mild Persistent Asthma. Ann Am
Thorac Soc, 2021.
18. Kamada, T., et al., Evidence-based clinical practice guidelines for
peptic ulcer disease 2020. J Gastroenterol, 2021. 56(4): p. 303-322.
19. Lanza, F.L., F.K. Chan, and E.M. Quigley, Guidelines for prevention
of NSAID-related ulcer complications. Am J Gastroenterol, 2009. 104(3):
p. 728-38.
20. Kim, W.-Y., et al., Underutilization of gastrointestinal prophylaxis
in high-risk chronic nonsteroidal anti-inflammatory drug users in Korea.
International Journal of Clinical Pharmacy, 2021. 43(3): p. 645-653.
21. Claxton, J.S., et al., A new model to predict major bleeding in
patients with atrial fibrillation using warfarin or direct oral
anticoagulants. PLoS One, 2018. 13(9): p. e0203599.
22. Glasheen, W.P., et al., Charlson Comorbidity Index: ICD-9 Update and
ICD-10 Translation. Am Health Drug Benefits, 2019. 12(4): p. 188-197.
Table Legends
Table 1. Baseline characteristics of the derivation and validation
cohort.
Table 2. The risk score for NSAID users.
Table 3. Model discrimination by derivation and validation cohorts.
Table 4. Accuracy of the risk prediction model using the cut-off values.
Figure Legends
Fig 1. Flowchart of selection of the study population.